ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer’s disease (AD). PRECISE-AD Phase 1b trial is fully enrolled and progressing on schedule, […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.